(Total Views: 393)
Posted On: 02/14/2020 11:42:41 AM
Post# of 72447
Re: bettingbig #62266
With those kind of facts and sales numbers for biologics, it seems obvious that Mo and the rest of us are using dramatically conservative numbers for expected revenue from IBD (and later IBS) due to the Brilacidin pill.
If one were to be candid, we could (and I will go as far as saying SHOULD) completely dominate this market with our Oralogik backed pill. If this is the case, the numbers Mo put up yesterday pale in comparison to what could be expected.
I am so glad we have LW doing our negotiations. Anybody without total cred in the biotech startup negotiating field as to being top flight professionals wouldn't have the balls to demand the value that I am sure LW will bring to the table for the IBD indication. The upfront monies now have to have gone up by a 7,8, or 9 digit number with the validation of the pill. We already have a good idea of the validation of the efficacy thru the POC for UP/UPS and thus what further milestones does a partnering BP have to hurdle other than a P3?
If one were to be candid, we could (and I will go as far as saying SHOULD) completely dominate this market with our Oralogik backed pill. If this is the case, the numbers Mo put up yesterday pale in comparison to what could be expected.
I am so glad we have LW doing our negotiations. Anybody without total cred in the biotech startup negotiating field as to being top flight professionals wouldn't have the balls to demand the value that I am sure LW will bring to the table for the IBD indication. The upfront monies now have to have gone up by a 7,8, or 9 digit number with the validation of the pill. We already have a good idea of the validation of the efficacy thru the POC for UP/UPS and thus what further milestones does a partnering BP have to hurdle other than a P3?
(6)
(1)
